Protego Biopharma closed an oversubscribed $130 million Series B to advance PROT‑001, its oral candidate for AL (light‑chain) amyloidosis, toward a pivotal study. The financing was led by established venture investors and strategics, signalling strong investor conviction in a small‑molecule approach to a protein‑misfolding rare disease. Protego says the capital will support regulatory interactions and a pivotal trial start next year. Company releases and investor commentary highlighted that the mechanism—stabilizing pathogenic light chains—differs from antibody approaches that faltered in prior pivotal studies, and could reshape treatment options if clinical efficacy and tolerability hold up.